3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Lymphoma
15
Breast Neoplasms
13
Leukemia, Myeloid, Acute
11
Carcinoma, Non-Small-Cell Lung
11
Glioblastoma
10
Lymphoma, Non-Hodgkin
8
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Follicular
8
Brain Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Mantle-Cell
7
Leukemia
7
Multiple Myeloma
6
Hodgkin Disease
6
Neoplasms
5
Myelodysplastic Syndromes
5
Lymphoma, T-Cell, Cutaneous
5
Lung Neoplasms
5
Gliosarcoma
5
Congenital Abnormalities
5
Breast Neoplasms, Male
5
Recurrence
4
Lymphoma, Large-Cell, Anaplastic
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Leukemia, Erythroblastic, Acute
4
Immunoblastic Lymphadenopathy
4
Interventions
Pemetrexed
12
Cisplatin
11
pembrolizumab
8
Carboplatin
6
Ipilimumab
5
Nivolumab
4
LMB-100
4
durvalumab
3
Gemcitabine
3
tremelimumab
2
tazemetostat
2
anetumab ravtansine
2
Vinorelbine
2
Plicamycin
2
Dexamethasone
2
Cyclophosphamide
2
Bevacizumab
2
vandetanib
1
tocilizumab
1
spartalizumab
1
ribociclib
1
rebastinib
1
pevonedistat
1
olaparib
1
niraparib
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
epacadostat
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma
×
Vorinostat
×
Clear all
NCT00128102
2020-10-26
MK-0683-014
Merck Sharp & Dohme LLC
Phase 3
Completed
661 enrolled
18 charts